Interferon-γ enhances promyelocytic leukemia protein expression in acute promyelocytic cells and cooperates with all-trans-retinoic acid to induce maturation of NB4 and NB4-R1 cells

Experimental and Therapeutic Medicine

Volumn 3, Issue 5, 2012, Pages 776-780

  He, Pengcheng ^a   Liu, Yanfeng ^a   Zhang, Mei ^a   Wang, Xiaoning ^a   Xi, Jieying ^a   Wu, Di ^a   Li, Jing ^a   Cao, Yunxin ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; All trans retinoic acid resistant; Interferon

Indexed keywords

CD11B ANTIGEN; GAMMA INTERFERON; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL MATURATION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LEUKEMIA CELL LINE; MICROSCOPY; MONOTHERAPY; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION;

EID: 84863385070     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.488     Document Type: Article

References (31)

1. Wang Z and Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515, 2008.
2. Zhou GB, Zhang J, Wang ZY, Chen SJ and Chen Z: Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci 362: 959-971, 2007.
3. Wang X, Yin Y, Ma P, et al: Apoptosis of human pancreatic carcinoma cells induced by all-trans retinoic acid and interferon. Chin J Cancer Res 21: 224-228, 2009.
4. Park HH, Kim M, Lee BH, et al: Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia. Ann Clin Lab Sci 36: 7-15, 2006.
5. Hoyer KK, Herling M, Bagrintseva K, et al: T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation. J Immunol 175: 864-873, 2005.
6. Montoro E, Lemus D, Echemendia M, et al: Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 55: 500-505, 2005.
7. Huang Y, Liu J, Wang LZ, Zhang WY and Zhu XZ: Neuroprotective effects of cyclooxygenase-2 inhibitor celecoxib against toxicity of LPS-stimulated macrophages toward motor neurons. Acta Pharmacol Sin 26: 952-958, 2005.
8. Owen J, Bates J and Lewis S: Differential effects of nitroblue tetrazolium on the hemodynamic responses elicited by activation of alpha(1)-adrenoceptors and 5-HT(2) receptors in conscious rats. Eur J Pharmacol 535: 248-252, 2006.
9. Choi HS, Kim JW, Cha YN and Kim C: A quantitative nitroblue tetrazolium assay for determining intracellular superoxide anion production in phagocytic cells. J Immunoassay Immunochem 27: 31-44, 2006.
10. Shi J, Zhang Y, Su JY, et al: Cytotoxicity of IFN-gamma-activated dendritic cells to freshly isolated acute myeloid leukemia cells. J Exp Hematol 13: 1071-1075, 2005.
11. Burchert A, Muller MC, Kostrewa P, et al: Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 28: 1429-1435, 2010.
12. Khoo TL, Vangsted AJ, Joshua D and Gibson J: Interferon-alpha in the treatment of multiple myeloma. Curr Drug Targets 12: 437-446, 2011.
13. Benz R, Stussi G and Fehr J: Interferon as an alternative to purine analogues in the treatment of hairy cell leukaemia. Brit J Haematol 148: 664-666, 2010.
14. Gupta V, Yi QL, Brandwein J, et al: Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL). Leukemia Res 29: 113-114, 2005.
15. Buonamici S, Li D, Mikhail F, et al: EVI1 abrogates interferon-alpha response by selectively blocking PML induction. J Biol Chem 280: 428-436, 2005.
16. Reineke EL and Kao HY: Targeting promyelocytic leukemia protein: a means to regulating PML nuclear bodies. Int Biol Sci 5: 366-376, 2009.
17. Chelbi-Alix MK, Vidy A, El Bougrini J and Blondel D: Rabies viral mechanisms to escape the IFN system: the viral protein P interferes with IRF-3, Stat1, and PML nuclear bodies. J Interferon Cytokine Res 26: 271-280, 2006.
18. Crowder C, Dahle O, Davis RE, Gabrielsen OS and Rudikoff S: PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. Blood 105: 1280-1287, 2005.
19. Dror N, Rave-Harel N, Burchert A, et al: Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells. J Biol Chem 282: 5633-5640, 2007.
20. Bernardi R, Papa A and Pandolfi PP: Regulation of apoptosis by PML and the PML-NBs. Oncogene 27: 6299-6312, 2008.
21. Li L and He DL: Transfection of promyelocytic leukemia in retrovirus vector inhibits growth of human bladder cancer cells. Acta Pharmacol Sin 26: 610-615, 2005.
22. Ravindranath Y, Gregory J and Feusner J: Treatment of acute promyelocytic leukemia by using all-trans retinoic acid (ATRA). Leukemia 18: 1576-1577, 2004.
23. Gupta V, Yib QL, Brandwein J, et al: Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy. Leuk Lymphoma 45: 469-480, 2004.
24. Zhang X, Yan X, Zhou Z, et al: Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science 328: 240-243, 2010.
25. Wang ZG, Delva L, Gaboli M, et al: Role of PML in cell growth and the retinoic acid pathway. Science 279: 1547-1551, 1998.
26. Abreu ELR, Baruffi MR, de Lima AS, et al: The co-expression of PML/RAR alpha and AML1/ETO fusion genes is associated with ATRA resistance. Brit J Haematol 128: 407-409, 2005.
27. Mueller BU, Pabst T, Fos J, et al: ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 107: 3330-3338, 2006.
28. Andrianifahanana M, Agrawal A, Singh AP, et al: Synergistic induction of the MUC4 mucin gene by interferon-gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways. Oncogene 24: 6143-6154, 2005.
29. Liu CH: Study on the synergic effect of all-trans retinoic acid combined with IFN-alpha on the proliferation and differentiation of HL-60 cells. Chin J Cell Mol Immunol 21: 637-639, 642, 2005.
30. Gu ZM, Wu YL, Zhou MY, et al: Pharicin B stabilizes retinoic acid receptor-alpha and presents synergistic differentiation induction with ATRA in myeloid leukemic cells. Blood 116: 5289-5297, 2010.
31. Wang J, Peng Y, Sun YW, et al: All-trans retinoic acid induces XAF1 expression through an interferon regulatory factor-1 element in colon cancer. Gastroenterology 130: 747-758, 2006